In Vitro: Ac-YVAD-CHO inhibits IL-1β in a dose-dependent manner, with mouse and human IC50 values of 2.5 and 0.7 μM. Ac-YVAD-CHO (0.01~100 μM) reduces the elevations of IL-lβ in the plasma and peritoneal fluid treated with LPS in a dose-related manner.
In Vivo: Ac-YVAD-CHO (10 mg/kg; i.p.; 1 hour) is absorbed from the peritoneal cavity, as well as cleared from the blood rapidly. Ac-YVAD-CHO (50 mg/kg; i.p.; 1 hour) drops precipitously to approximately 1 and 0.2 μM at 30 and 60 minutes after injection. Ac-YVAD-CHO (30 mg/kg; i.p.; 6 hours) suppresses IL-1β levels.